Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-135 and Daclatasvir in Genotype 1 Chronic Hepatitis C
NCT01842451Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VX-135 in hepatitis C (HCV) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and tolerability as assessed by adverse events, vital signs, ECGs, echocardiograms, and laboratory assessments up to 64 weeks. Started Jun 2013; status: completed.
02
Drugs
VX-135
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01842451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842451.